Studies related to HbA1c and Salvia hispanica

Supplementation Of Conventional Therapy With The Novel Grain Salba (Salvia Hispanica L.) Improves Major And Emerging Cardiovascular Risk Factors In Type 2 Diabetes: Results Of A Randomized Controlled Trial

Effect None
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 20
Sex n/a
Age Range 45-64, 65+
Body Types Obese, Overweight
Notes for this study:
C-reactive protein increased in control and not in chia ingestion (causing a significant difference) and both fibrinogen and blood pressure were reduced with chia consumption at 15g per 1000kcal in type II diabetics over 12 weeks. No influence on standard biomarkers of glucose or lipid metabolism.
Funding issues for this study:
Product supplied by Salba Nutritional Solutions, affiliation and influence of this company unknown (likely a nonconcern)